Purpose
To determine whether a combination of intravitreal aflibercept (IVA) and pranoprofen eyedrops or nutraceutical support provides additional benefit over IVA monotherapy for the treatment of choroidal neovascularization (CNV) in age‐related macular degeneration.
Methods
This was a prospective, randomized, pilot study in 60 patients with treatment‐naïve CNV. Patients were randomized 1:1:1 into 3 groups: aflibercept monotherapy (AM), aflibercept plus pranoprofen (AP), or aflibercept plus nutraceutical (AN) tablets containing multivitamin antioxidant and mineral supplementation plus omega‐3.
Results
At 12 months, all groups showed significant improvement in both best‐corrected visual acuity (BCVA) and central retinal thickness (CRT). The mean BCVA change from baseline to 12 months was –0.26 ± 0.06 LogMAR,–0.30 ± 0.06 LogMAR, and –0.24 ± 0.04 LogMAR in the AM, AP, and AN groups, respectively. The mean CRT change from baseline to 12 months was –76.9 ± 10.9 μm, –129 ± 19.9 μm, and –105 ± 11.6 μm in the AM, AP, and AN groups, respectively. The AN group required 1 less IVA injection than the AM group.
Conclusion and Implications
Compared with AM, both combination groups acted synergistically, although no significant benefits in BCVA were found over AM. Nutraceutical support with omega‐3 leads to a reduced need for IVA.
http://bit.ly/2WjRLRY
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.